


I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on November 4, 2004

Glenn P. Ladwig  
Glenn P. Ladwig, Patent Attorney



INFORMATION DISCLOSURE  
STATEMENT

Examining Group 1642

Patent Application

Docket No. USF-T187XC1

Serial No. 10/734,548

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : (Not yet assigned)  
Art Unit : 1642  
Applicants : Shyam S. Mohapatra, Homero Gabriel San Juan Vergara  
Serial No. : 10/734,548  
Filed : December 12, 2003  
For : Protein Kinase C as a Target for the Treatment of Respiratory Syncytial Virus

MS AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. Copies of the foreign patents and non-patent publications cited are enclosed.

The applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

Glenn P. Ladwig  
Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800


Address: P.O. Box 142950

Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (7 pages); copies of some references cited therein.

J:\USFT187XC1\PTO\IDS.pto.doc/DNB/mv



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/734,548	
			Filing Date	December 12, 2003	
			First Named Inventor	Shyam S. Mohapatra	
			Art Unit	1642	
			Examiner Name		
Sheet	1	of	7	Attorney Docket Number	USF-T187XC1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	U1	US-2003/0148989 A1	08-07-2003	Bennett et al.	All
	U2	US-2002/0165158 A1	11-07-2002	King	All
	U3	US-2003/0068333 A1	04-10-2003	Mohapatra et al.	All
	U4	US-6,489,306 B2	12-03-2002	Mohapatra et al.	All
	U5	US-5,783,405	07-21-1998	Mochly-Rosen et al.	All
	U6	US-5,621,101	04-15-1997	Lewis et al.	All
	U7	US-5,621,098	04-15-1997	Heath, Jr. et al.	All
	U8	US-5,616,577	04-01-1997	Nambi et al.	All
	U9	US-5,578,590	11-26-1996	Grunicke al.	All

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	F1	WO 94/29455 A1	12-22-1994	Institut National de la Sante et de la Recherche Medicale	Abstract	
	F2	WO 93/20101 A1	10-14-1993	Glaxo S.A.	All	
	F3					
	F4					
	F5					

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/734,548
				Filing Date	December 12, 2003
				First Named Inventor	Shyam S. Mohapatra
				Art Unit	1642
				Examiner Name	
Sheet	2	of	7	Attorney Docket Number	USF-T187XC1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	U10	US-5,545,636	08-13-1996	Heath, Jr. et al.	All
	U11	US-5,491,242	02-13-1996	Gillig et al.	All
	U12	US-5,488,167	01-30-1996	Hudlicky	All
	U13	US-5,481,003	01-02-1996	Gillig et al.	All
	U14	US-5,461,146	10-24-1995	Lewis et al.	All
	U15	US-5,270,310	12-14-1993	Bell et al.	All
	U16	US-5,216,014	06-01-1993	Jiang et al.	All
	U17	US-5,204,370	04-20-1993	Jiang et al.	All
	U18	US-5,141,957	08-25-1992	Jiang et al.	All
	U19	US-4,990,519	02-05-1991	Jones et al.	All
	U20	US-4,937,232	06-26-1990	Bell et al.	All

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	F1					
	F2					
	F3					
	F4					
	F7					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/734,548	
			Filing Date	December 12, 2003	
			First Named Inventor	Shyam S. Mohapatra	
			Group Art Unit	1642	
			Examiner Name		
Sheet	3	of	7	Attorney Docket Number	USF-T187XC1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	R1	BITKO, V. and BARIK, S. "Persistent activation of RelA by respiratory syncytial virus involves protein kinase C, underphosphorylated IxB $\beta$ , and sequestration of protein phosphatase 2A by the viral phosphoprotein" <i>J. Virol.</i> , 1998, 72:5610-5618.		
	R2	BITKO, V. <i>et al.</i> "Transcriptional induction of multiple cytokines by human respiratory syncytial virus requires activation of NF- $\kappa$ B and is inhibited by sodium salicylate and aspirin" <i>Virology</i> , 1997, 232:369-378.		
	R3	BROWN, G. <i>et al.</i> "Respiratory syncytial virus assembly occurs in GM1-rich regions of the host-cell membrane and alters the cellular distribution of tyrosine phosphorylated caveolin-1" <i>J. Gen. Virol.</i> , 2002, 83:1841-1850.		
	R4	BROWN, G. <i>et al.</i> "Caveolin-1 is incorporated into mature respiratory syncytial virus particles during virus assembly on the surface of virus-infected cells" <i>J. Gen. Virol.</i> , 2002, 83:611-621.		
	R5	BUDGE, P. <i>et al.</i> "RhoA-derived peptide dimmers share mechanistic properties with other polyanionic inhibitors of respiratory syncytial virus (RSV), including disruption of viral attachment and dependence on RSV G" <i>J. Virol.</i> , 2004, 78:5015-5022.		
	R6	CARPENTER, L. <i>et al.</i> "Respiratory syncytial virus and TNF $\alpha$ induction of chemokine gene expression involves differential activation of Rel A and NF- $\kappa$ B" <i>BMC Infect. Dis.</i> , 2002, 2(1):5.		
	R7	CHEN, W. <i>et al.</i> "Activation of ERK2 by respiratory syncytial virus in A549 cells is linked to the production of interleukin 8" <i>Exp. Lung Res.</i> , 2000, 26:13-26.		
	R8	CONSTANTINESCU, S. <i>et al.</i> "Effects of protein kinase C inhibitors on viral entry and infectivity" <i>FEBS</i> , 1991, 292:31-33.		
	R9	DISATNIK, M-H. <i>et al.</i> "Sequential activation of individual PKC isozymes in integrin-mediated muscle cell spreading: a role for MARCKS in an integrin signaling pathway" <i>J. Cell. Sci.</i> , 2002, 115:2151-2163.		
	R10	DUNCAN, M. <i>et al.</i> "Microbial entry through caveolae: variations on a theme" <i>Cell. Microbiol.</i> , 2002, 4:783-791.		
	R11	EICHHOLTZ, T. <i>et al.</i> "A myristoylated pseudosubstrate peptide, a novel protein kinase C inhibitor" <i>J. Biol. Chem.</i> , 1993, 268:1982-1986.		
	R12	GODSON, C. <i>et al.</i> "Inhibition of expression of protein kinase C $\alpha$ by antisense cDNA inhibits phorbol ester-mediated Arachidonate release" <i>J. Biol. Chem.</i> , 1993, 268:11946-11950.		
	R13	GOWER, T. <i>et al.</i> "RhoA is activated during respiratory syncytial virus infection" <i>Virol.</i> , 2001, 283:188-196.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/734,548	
			Filing Date	December 12, 2003	
			First Named Inventor	Shyam S. Mohapatra	
			Group Art Unit	1642	
			Examiner Name		
Sheet	4	of	7	Attorney Docket Number	USF-T187XC1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	R14	HALLAK, L.K. <i>et al.</i> "Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection" <i>J. Virol.</i> , 2000, 74:10508-10513.		
	R15	HANNUN, Y. <i>et al.</i> "The adriamycin-iron(III) complex is a potent inhibitor of protein kinase C" <i>J. Biol. Chem.</i> , 1989, 264:9960-9966.		
	R16	HANNUN, Y. <i>et al.</i> "Aminoacridines, potent inhibitors of protein kinase C" <i>J. Biol. Chem.</i> , 1988, 263:5124-5131.		
	R17	HARRIS, T. <i>et al.</i> "A myristoylated pseudosubstrate peptide inhibitor of protein kinase C: effects on glucose- and carbachol-induced insulin secretion" <i>Mol. Cell. Endocrin.</i> , 1996, 121:133-141.		
	R18	KONG, X. <i>et al.</i> "Respiratory syncytial virus infection activates STAT signaling in human epithelial cells" <i>Biochem. Biophys. Res. Comm.</i> , 2003, 306:616-622.		
	R19	KONG, X. <i>et al.</i> "ERK-1/2 activity is required for efficient RSV infection" <i>FEBS Letters</i> , 2004, 559:33-38.		
	R20	LEHEL, C. <i>et al.</i> "A chemiluminescent microtiter plate assay for sensitive detection of protein kinase activity" <i>Anal. Biochem.</i> , 1997, 244:340-346.		
	R21	LEVESQUE, L. <i>et al.</i> "Antisense oligonucleotides targeting human protein kinase C- $\alpha$ inhibit phorbol ester-induced reduction of bradykinin-evoked calcium mobilization in A549 cells" <i>Molecul. Pharmac.</i> , 1997, 51:209-216.		
	R22	LIEBMANN, C. <i>et al.</i> "Regulation of MAP kinase activity by peptide receptor signalling pathway: Paradigms of multiplicity" <i>Cell. Signalling</i> , 2001, 13:777-785.		
	R23	LU, Z. <i>et al.</i> "Activation of protein kinase C triggers its ubiquitination and degradation" <i>Molec. Cell. Biol.</i> , 1998, 18:839-845.		
	R24	MALLADI, V. <i>et al.</i> "Enteropathogenic <i>Escherichia coli</i> outer membrane proteins induce changes in cadherin junctions of Caco-2 cells through activation of PKC $\alpha$ " <i>Microbes and Infect.</i> , 2004, 6:38-50.		
	R25	MARTINEZ, I. and MELERO, J. "Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans" <i>J. Gen. Virol.</i> , 2000, 81:2715-2722.		
	R26	MCCURDY, L. and GRAHAM, B. "Role of plasma membrane lipid microdomains in respiratory syncytial virus filament formation" <i>J. Virol.</i> , 2003, 77:1747-1756.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/734,548	
			Filing Date	December 12, 2003	
			First Named Inventor	Shyam S. Mohapatra	
			Group Art Unit	1642	
			Examiner Name		
Sheet	5	of	7	Attorney Docket Number	USF-T187XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R27	MEIER, O. <i>et al.</i> "Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake" <i>J. Cell Biol.</i> , 2002, 158:1119-1131.	
	R28	MESSING, R.O. <i>et al.</i> "Chronic ethanol exposure increases levels of protein kinase C $\delta$ and $\epsilon$ and Protein kinase C-mediated phosphorylation in cultured neural cells" <i>J. Biol. Chem.</i> , 1991, 266:23428-23432.	
	R29	MINEO, C. and ANDERSON, R. "Potocytosis" <i>Histochem. Cell Biol.</i> , 2001, 116:109-118.	
	R30	MOCHLY-ROSEN, D. and GORDON, A. "Anchoring proteins for protein kinase C: a means for isozyme selectivity" <i>FASEB J.</i> , 1998, 12:35-42.	
	R31	MONICK, M. <i>et al.</i> "Respiratory syncytial virus infection results in activation of multiple protein kinase C isoforms leading to activation of mitogen-activated protein kinase" <i>J. Immun.</i> , 2001, 166:2681-2687.	
	R32	NAKANO, M. <i>et al.</i> "The first step of adenovirus type 2 disassembly occurs at the cell surface, independently of endocytosis and escape to the cytosol" <i>J. Virol.</i> , 2000, 74:7085-7095.	
	R33	NARANATT, P. <i>et al.</i> "Kaposi's sarcoma-associated herpesvirus induces the phosphatidylinositol 3-kinase-PKC- $\zeta$ -MEK-ERK signaling pathway in target cells early during infection: implications for infectivity" <i>J. Virol.</i> , 2003, 77:1524-1539.	
	R34	PAREKH, D. <i>et al.</i> "Multiple pathways control protein kinase C phosphorylation" <i>The EMBO J.</i> , 2000, 19:496-503.	
	R35	PELKMANS, L. <i>et al.</i> "Local actin polymerization and dynamin recruitment in SV40-induced internalization of caveolae" <i>Science</i> , 2002, 296:535-539.	
	R36	PREVOSTEL, C. <i>et al.</i> "Protein kinase Ca actively downregulates through caveolae-dependent traffic to an endosomal compartment" <i>J. Cell Sci.</i> , 2000, 113:2575-2584.	
	R37	RAZINKOV, V. <i>et al.</i> "RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein" <i>Chem. &amp; Biol.</i> , 2001, 8:645-659.	
	R38	ROOT, C. <i>et al.</i> "Entry of influenza viruses into cells is inhibited by a highly specific protein kinase C inhibitor" <i>J. Gen. Virol.</i> , 2000, 81:2697-2705.	
	R39	SAN-JUAN, H. <i>et al.</i> "Activation of PKC isozymes in normal human bronchial epithelial cells by respiratory syncytial virus infection" <i>J. Allergy Clin. Immunol.</i> , 2002, 109(1):S362, abstract no. 1128.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/734,548	
			Filing Date	December 12, 2003	
			First Named Inventor	Shyam S. Mohapatra	
			Group Art Unit	1642	
			Examiner Name		
Sheet	6	of	7	Attorney Docket Number	USF-T187XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R40	SIECZKARSKI, S. <i>et al.</i> "Role of protein kinase C $\beta$ II in influenza virus entry via late endosomes" <i>J. Virol.</i> , 2003, 77:460-469.	
	R41	SIMÕES, E. "Respiratory syncytial virus infection" <i>The Lancet</i> , 1999, 354:847-852.	
	R42	SOH, J-W. <i>et al.</i> "Novel roles of specific isoforms of protein kinase C in activation of the c-fos serum response element" <i>Molec. Cell. Biol.</i> , 1999, 19:1313-1324.	
	R43	SUKUMARAN, S. and PRASADARAO, N. "Regulation of protein kinase C in <i>Escherichia coli</i> K1 invasion of human brain microvascular endothelial cells"	
	R44	TECHAARPORNKUL, S. <i>et al.</i> "Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene" <i>J. Virol.</i> , 2001, 75:6825-6834.	
	R45	TOULLEC, D. <i>et al.</i> "The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C" <i>J. Biol. Chem.</i> , 1991, 266:15771-15781.	
	R46	URBACH, V. <i>et al.</i> "Cellular mechanisms for apical ATP effects on intracellular pH in human bronchial epithelium" <i>J. Physiol.</i> , 2002, 543.1:13-21.	
	R47	VANDERPLASSCHEN, A. <i>et al.</i> "Intracellular and extracellular vaccinia virions enter cells by different mechanisms" <i>J. Gen. Virol.</i> , 1998, 79:877-887.	
	R48	VANDERPLASSCHEN, A. and SMITH, G. "A novel virus binding assay using confocal microscopy: demonstration that the intracellular and extracellular vaccinia virions bind to different cellular receptors" <i>J. Virol.</i> , 1997, 71:4032-4041.	
	R49	VILLALBA, M. <i>et al.</i> "Vav1/Rac-dependent actin cytoskeleton reorganization is required for lipid raft clustering in T cells" <i>J. Cell Biol.</i> , 2001, 155:331-338.	
	R50	WAGNER, S. <i>et al.</i> "Analysis of the subcellular distribution of protein kinase $C\alpha$ using PKC-GFP fusion proteins" <i>Exp. Cell Res.</i> , 2000, 258:204-214.	
	R51	WANASKI, S. <i>et al.</i> "Caveolin Scaffolding region and the membrane binding region of Src form lateral membrane domains" <i>Biochem.</i> , 2003, 42:42-56.	
	R52	WANG, Y. <i>et al.</i> "Metabolic stress opens $K^+$ channels in hepatoma cells through a $Ca^{2+}$ - and protein kinase $C\alpha$ -dependent mechanism" <i>J. Biol. Chem.</i> , 1996, 271:18107-18113.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/734,548	
			Filing Date	December 12, 2003	
			First Named Inventor	Shyam S. Mohapatra	
			Group Art Unit	1642	
			Examiner Name		
Sheet	7	of	7	Attorney Docket Number	USF-T187XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R53	WYATT, T. <i>et al.</i> "Stimulation of protein kinase C activity by tumor necrosis factor- $\alpha$ in bovine bronchial epithelial cells" <i>Am. J. Physiol.</i> , 1997, 273:L1007-1013.	
	R54	AHMAD, S. <i>et al.</i> "Antisense expression of protein kinase C $\alpha$ inhibits the growth and tumorigenicity of human glioblastoma cells" <i>Neurosurg.</i> , 1994, 35:904-908.	
	R55	ANDERSON, R.G.W. "The caveolae membrane" <i>Ann. Rev. Biochem.</i> , 1998, 67:199-225.	
	R56	CHAKRAVARTHY, B.R. <i>et al.</i> "The direct measurement of protein kinase C (PKC) activity in isolated membranes using a selective peptide substrate" <i>Anal. Biochem.</i> , 1991, 196:144-150.	
	R57	HIDAKA, H. <i>et al.</i> "Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C" <i>Biochemistry</i> , 1984, 23:5036-5041.	
	R58	KITANO, T. <i>et al.</i> "Assay and purification of protein kinase C" <i>Meth. Enzymol.</i> , 1986, 124:349-352.	
	R59	KOBAYASHI, E. <i>et al.</i> "Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C" <i>Biochem. Biophys. Res. Commun.</i> , 1989, 159(2):548-553.	
	R60	MEYER, T. <i>et al.</i> "A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and <i>in vitro</i> anti-proliferative as well as <i>in vivo</i> anti-tumor activity" <i>Int. J. Cancer</i> , 1989, 43:851-856.	
	R61	SCHECHTMAN, D. and MOCHLY-ROSEN, D. "Isozyme-specific inhibitors and activators of protein kinase C" <i>Methods Enzymol.</i> , 2002, 345:470-489.	
	R62	SOUROUJON, M.C. and MOCHLY-ROSEN, D. "Peptide modulators of protein-protein interactions in intracellular signaling" <i>Nat. Biotechnol.</i> , 1998, 16:919-924.	
	R63	TAMAOKI, T. <i>et al.</i> "Staurosporine, a potent inhibitor of phospholipids/Ca <sup>++</sup> dependent protein kinase" <i>Biochem. Biophys. Res. Commun.</i> , 1986, 135(2):397-402.	
	R64		
	R65		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.